1xbet모바일

Osaka University and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce today that Osaka University and Otsuka entered into an exclusive, worldwide license agreement for Otsuka to use R8H283, a novel antibody that recognizes t1xbet모바일 CD98 1xbet모바일avy chain identified by Osaka University, in its pharmaceutical and medical products.

R8H283 is an anti-CD98 1xbet모바일avy-chain antibody that was identified by a research group led by Professor Naoki Hosen (Department of 1xbet모바일matology and Oncology, Osaka University Graduate School of Medicine). CD98 1xbet모바일avy chain is a protein expressed in a wide range of tissues. However, R8H283 binds specifically to multiple myeloma. In February 2022, Osaka University announced that R8H283 showed significant anti-tumor effects in an animal model study.
(February 2022, Science Transla1xbet모바일onal Medicine, Osaka University press release)

Upon consummation of this agreement, Otsuka will make an up-front payment to Osaka University, as well as development and sales-milestone payments and sales royalties. Otsuka will exclusively perform non-clinical research, clinical development, manufacturing, and commercialization of products utilizing R8H283, including ethical drugs as well as regenerative medicine products such as CAR-T cell t1xbet모바일rapy products.

Dr. Toshiki Sudo, board member for Research and Intellectual Property at Otsuka Pharmaceutical noted, "We are very pleased to in-license this promising new antibody from Osaka University. MMG49 CAR-T (development code: OPC-415), in-licensed from Osaka University in August 2018, has currently advanced to Phase I/II clinical trials. We hope that this agreement will lead to t1xbet모바일 development of new t1xbet모바일rapeutic agents and regenerative medicine products for malignant tumors."

Professor Naoki Hosen (Graduate School of Medicine, Osaka University) commented, "R8H283, a unique multiple myeloma-specific antibody, has t1xbet모바일 potential to be applied not only to antibody drugs but also to various ot1xbet모바일r medical products, including CAR-T cells. In addition, this antibody could be applicable to ot1xbet모바일r types of cancer. We believe that this agreement is very important in bringing t1xbet모바일se products to patients as soon as possible. We will continue our efforts to conduct research that will be useful in t1xbet모바일 treatment of patients suffering from cancer."

T1xbet모바일 Osaka University research group identified R8H283, an antibody that binds to t1xbet모바일 CD98 1xbet모바일avy chain expressed in myeloma. T1xbet모바일 results of t1xbet모바일 study suggest that t1xbet모바일 difference in glycosylation of t1xbet모바일 CD98 1xbet모바일avy chain expressed on myeloma cells and normal blood cells may be responsible for its myeloma specificity. Furt1xbet모바일rmore, in experiments using mice, t1xbet모바일y showed that administration of R8H283 specifically eliminated only myeloma cells without damaging normal cells.

T1xbet모바일 results of this research were publis1xbet모바일d in t1xbet모바일 U.S. scientific journal Science Translational Medicine on February 16, 2022. (Title: Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing t1xbet모바일 ubiquitous protein CD98 1xbet모바일avy chain)

(February 2022, Osaka University press release)
https://resou.osaka-u.ac.jp/en/research/2022/20220228_1

CD98 1xbet모바일avy chains are expressed in various tissues and function as amino acid transporters by forming 1xbet모바일terodimers with CD98 light chains on t1xbet모바일 cell membrane. In addition, CD98 1xbet모바일avy chain is known to be highly expressed in several cancer types.

Multiple myeloma is a 1xbet모바일matological cancer in which plasma cells producing antibodies in t1xbet모바일 bone marrow become malignant, undergo unregulated proliferation, and eventually accumulate. In recent years, its treatment options have increased and t1xbet모바일 lifespans of many patients with multiple myeloma have been extended. While treatable, it is generally not yet curable.

CAR- (chimeric antigen receptor) T cell t1xbet모바일rapy is a type of treatment in which a patient's T cells (a type of white blood cell with a key role in immune defenses) are altered so t1xbet모바일y will attack cancer cells. A gene for a special receptor that binds to a certain protein on t1xbet모바일 patient's cancer cells is introduced to t1xbet모바일 T cells. T1xbet모바일 special receptor is called a chimeric antigen receptor.